CLINICAL TRIALS PROFILE FOR PINDOLOL

All Clinical Trials for PINDOLOL

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00007592 ↗	Hypertension Screening and Treatment Program	Completed	US Department of Veterans Affairs		1989-06-01	Hypertension is one of the most common medical problems in the United States and in the VA health care system. It has been well-documented that hypertension can be effectively treated. However, there remain important unresolved clinical questions in the area of antihypertensive treatment. For example, how much is mortality affected by visit compliance, blood pressure control and type of antihypertensive agent? Or, are some regimens associated with more morbidity than others? Or, are there inexpensive regimens that are as effective as more expensive regimens? The amount of data that is available from this demonstration project (currently 6,100 patients) will help address these questions. The answers to these questions should result in better care for veterans with hypertension.
NCT00007592 ↗	Hypertension Screening and Treatment Program	Completed	VA Office of Research and Development		1989-06-01	Hypertension is one of the most common medical problems in the United States and in the VA health care system. It has been well-documented that hypertension can be effectively treated. However, there remain important unresolved clinical questions in the area of antihypertensive treatment. For example, how much is mortality affected by visit compliance, blood pressure control and type of antihypertensive agent? Or, are some regimens associated with more morbidity than others? Or, are there inexpensive regimens that are as effective as more expensive regimens? The amount of data that is available from this demonstration project (currently 6,100 patients) will help address these questions. The answers to these questions should result in better care for veterans with hypertension.
NCT00149110 ↗	Chronos: the Use of Chronobiological Treatment in Depression	Completed	Eli Lilly and Company	N/A	2005-09-01	The primary objective of the present study is to examine whether the combination of the antidepressant duloxetine and chronotherapeutic methods (including sleep deprivation, light therapy, and maintaining a regular sleep-wake rhythm) in patient with major depression, will induce an immediate improvement from depression and whether this antidepressive effect will be maintained in the long term (29 weeks). Patient will be randomised to the above mentioned treatment or to an active group receiving exercise.
NCT00149110 ↗	Chronos: the Use of Chronobiological Treatment in Depression	Completed	The County of Frederiksborg	N/A	2005-09-01	The primary objective of the present study is to examine whether the combination of the antidepressant duloxetine and chronotherapeutic methods (including sleep deprivation, light therapy, and maintaining a regular sleep-wake rhythm) in patient with major depression, will induce an immediate improvement from depression and whether this antidepressive effect will be maintained in the long term (29 weeks). Patient will be randomised to the above mentioned treatment or to an active group receiving exercise.
NCT00149110 ↗	Chronos: the Use of Chronobiological Treatment in Depression	Completed	Hillerod Hospital, Denmark	N/A	2005-09-01	The primary objective of the present study is to examine whether the combination of the antidepressant duloxetine and chronotherapeutic methods (including sleep deprivation, light therapy, and maintaining a regular sleep-wake rhythm) in patient with major depression, will induce an immediate improvement from depression and whether this antidepressive effect will be maintained in the long term (29 weeks). Patient will be randomised to the above mentioned treatment or to an active group receiving exercise.
NCT00159146 ↗	Trial of Pindolol Augmentation in Venlafaxine Treated Patients With Major Depression	Terminated	Tvergaards Foundation	N/A	2002-08-01	This study investigates the hypothesis that pindolol can accelerate the response to antidepressants in patients with major depression treated with venlafaxine.
NCT00159146 ↗	Trial of Pindolol Augmentation in Venlafaxine Treated Patients With Major Depression	Terminated	Wyeth is now a wholly owned subsidiary of Pfizer	N/A	2002-08-01	This study investigates the hypothesis that pindolol can accelerate the response to antidepressants in patients with major depression treated with venlafaxine.

Clinical Trial Conditions for PINDOLOL

Condition Name

Condition Name for PINDOLOL
Intervention	Trials
Major Depression	3
Hypertension	2
Major Depressive Disorder	2
Cardiac Failure	2

Condition MeSH

Condition MeSH for PINDOLOL
Intervention	Trials
Depressive Disorder	7
Depression	6
Depressive Disorder, Major	5
Disease	2

Clinical Trial Locations for PINDOLOL

Trials by Country

Trials by Country for PINDOLOL
Location	Trials
United States	17
Denmark	4
Switzerland	2
Spain	2
Puerto Rico	1

Trials by US State

Trials by US State for PINDOLOL
Location	Trials
New York	3
California	2
Florida	2
District of Columbia	1
North Carolina	1

Clinical Trial Progress for PINDOLOL

Clinical Trial Phase

Clinical Trial Phase for PINDOLOL
Clinical Trial Phase	Trials
Phase 4	3
Phase 3	1
Phase 2/Phase 3	1

Clinical Trial Status

Clinical Trial Status for PINDOLOL
Clinical Trial Phase	Trials
Completed	7
Terminated	4
Enrolling by invitation	2

Clinical Trial Sponsors for PINDOLOL

Sponsor Name

Sponsor Name for PINDOLOL
Sponsor	Trials
Weill Medical College of Cornell University	2
University Hospital, Basel, Switzerland	2
Hillerod Hospital, Denmark	2

Sponsor Type

Sponsor Type for PINDOLOL
Sponsor	Trials
Other	26
Industry	8
NIH	4